Phase II Safety Single-arm Study of CDK4/6 Inhibition With Palbociclib in Hospitalized, Moderate COVID-19 Cases to Prevent Thromboinflammation

COVID-19 Clinical Trial

— CDK6COV  

Official title:

Phase II Safety Single-arm Study of CDK4/6 Inhibition With Palbociclib in Hospitalized, Moderate COVID-19 Cases to Prevent Thromboinflammation

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05371275
• Other study ID #: BXAI-001
• Secondary ID: 2021-006770-24
• Status: Withdrawn
• Phase: Phase 2
• Start date: April 21, 2022
• Est. completion date: December 2022

Study information

• Verified date: November 2022
• Source: biotx.ai GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a one-site, interventional, prospective, single-arm, open-label, controlled phase-IIa trial evaluating the safety and efficacy of palbociclib in hospitalized, moderate COVID- 19 cases.

Description:

The study will include hospitalized, moderate COVID-19 cases that have a risk of respiratory failure. The study will generally consist of: - A short screening phase (1 day) before enrollment and thus treatment decision. - A 21 day treatment phase with one "cycle" of palbociclib - An up to day 90 Safety Follow-Up Phase The first three patients will be enrolled and treated one by one; the independent safety data review committee (ISRC) will review each patient after D21 before enrollment of the subsequent patient is permitted.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2022
• Est. primary completion date: October 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. age >= 18 years

2. positive PCR COVID-19 test (max. 72h old)

3. known vaccination status

4. ANC >= 1,000/mm3 and platelets >= 50,000/mm3

5. willingness to participate (written informed consent)

6. established risk factors for a severe course of COVID-19-disease, for example:

adipositas, cardiovascular disease including arterial hypertension, advanced age > 60, chronic lung disease including asthma, diabetis type I or II, chronic kidney disease, chronic liver disease

7. Oxygen supply: = 2 liters/minute

8. Women of childbearing potential (WOCBP): must have a negative pregnancy test (ß- HCG urine or serum test) a. WOCBP is considered as i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. b. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. c. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.

9. Use of highly effective contraception method

1. All potentially fertile participants, or their male partners, must use an adequate, medically approved method of contraception or agree to abstinence during and at least 3 weeks (females) and 14 weeks (males) after treatment with Palbociclib.

2. For females, highly effective birth control should be used, i.e., combined hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable), intrauterine device, or intrauterine hormone-releasing system, bilateral tubal occlusion and vasectomized partner. As there is no information available on the interaction of palbociclib with oral contraceptives, a double-barrier contraception is necessary in this case.

3. Males must agree to use a condom for at least 14 weeks after the treatment phase.

Exclusion Criteria:

1. age < 18 year

2. ECOG >= 3

3. ANC < 1,000/mm3 and platelets < 50,000/mm3

4. intensive care patient

5. treatment with any other CDK4/6 Inhibitor

6. pregnant or breast-feeding women

7. patients receiving immunosuppressants for other diseases (e.g. rheumatoid arthritis)

8. known malignancy in the past 5 years other than basal cell carcinoma

9. baseline O2-Saturation < 92%

10. participation in any other medical device or medicinal product study within the previous month

Related Conditions & MeSH terms

• COVID-19

Intervention

Drug:
• Palbociclib
125 mg of palbociclib once daily for 21 consecutive days

Locations

Country	Name	City	State
Germany	Universitätsklinikum Brandenburg an der Havel	Brandenburg an der Havel

Sponsors (1)

Lead Sponsor	Collaborator
biotx.ai GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of treatment-related treatment discontinuation after 21 days of palbociclib treatment		21 days
Secondary	Time to freedom from oxygenation, measured in days after the first treatment dose.		90 days
Secondary	Time to transfer to ICU		90 days
Secondary	Course of neutrophil cell count during treatment		21 days
Secondary	Course of D-dimer during treatment		21 days
Secondary	Rate of thrombotic events during treatment		21 days
Secondary	Course of O2 saturation during treatment		21 days
Secondary	Rate of persisting symptoms after 3, 6, 9 and 12 months		Through completion of safety follow-up up to 12 month
Secondary	Dose reduction rate		21 days
Secondary	Rate of (S)AEs at day 21		at day 21